Modality
Degrader
MOA
MDM2i
Target
IL-13
Pathway
JAK/STAT
EpilepsyFSGSCLL
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
~May 2017
→ ~Aug 2018
Phase 3
~Nov 2018
→ ~Feb 2020
NDA/BLA
~May 2020
→ ~Aug 2021
Approved
Nov 2021
→ Oct 2030
ApprovedCurrent
NCT07945630
1,082 pts·FSGS
2021-11→2030-10·Not yet recruiting
1,082 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2030-10-104.5y awayPh3 Readout· FSGS
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Not yet…
Catalysts
Ph3 Readout
2030-10-10 · 4.5y away
FSGS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07945630 | Approved | FSGS | Not yet recr... | 1082 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Capiglumide | BioNTech | Preclinical | CGRP |